How MHOA Is Protecting Our Patients and Staff from
Your health and the health of our staff are of the upmost importance. In order to safely respond to the outbreak of COVID-19, we have instituted […]
Scientists have discovered more about the mysterious role of epigenetics, the study of how genes change, in controlling the way cancers develop. October, 2022
Often called “dark matter”, it could alter the way cancer is detected and treated, research from The Institute of Cancer Research suggests.
Exploring Emerging IO Combinations in Hepatocellular Carcinoma
A number of trials are exploring immune-oncology (IO) therapies in combination with VEGF antibodies, tyrosine kinase inhibitors (TKIs), and other IO agents as potential new strategies for patients with hepatocellular carcinoma. A presentation by Richard S. Finn, MD, during the American Association for Cancer Research Special Conference, focused on phase 3 combination studies in that setting.
UArizona researchers develop ‘Goldilocks drug’ to treat triple-negative breast cancer October, 2022
University of Arizona researchers have been working for decades to develop a drug that so specifically targets a deadly kind of breast cancer that there are little to no toxic side effects.
HER2-Low Breast Cancer
More metastatic breast cancer patients may be eligible to receive a treatment recently approved by the U.S. Food and Drug Administration (FDA) for a newly defined category called “HER2-low” metastatic breast cancer. October, 2022
Nanoparticles maximize cancer drug’s STING in preclinical tests October, 2022
Researchers have turned to drug delivery nanoparticles to maximize the anti-cancer STING of a molecule, pointing to a possible way to unlock the potential of a pathway that has caught the eye of the industry.
These DNA-Damaging Molecules May Be The Link Between Colon Cancer And IBD Health October, 2022
Scientists have discovered DNA-damaging molecules made by gut bacteria that may help explain why people with inflammatory bowel disease (IBD) have higher rates of colorectal cancer than those without the condition.
FDA Approves New Immunotherapy for Advanced Liver Cancer
Imjudo plus Imfinzi improved overall survival compared with standard targeted therapy for hepatocellular carcinoma.
Triple-negative breast cancer: Experimental treatment shows promise October 31. 2022
An estimated 2.3 million womenTrusted Source around the world received a diagnosis of breast cancer in 2020. That same year, about 685,000 women globally died from the disease.
Gut-dwelling bacterium singled out as the possible cause of colorectal cancer Some strains of the ‘Morganella morganii’ microbe produce molecules that are toxic for human DNARead Article
FDA Grants Accelerated Approval to Teclistamab-cqyv in Relapsed/Refractory Multiple MyelomaRead Article
Scientific News:Recent approval of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma, based on results from the phase 3 HIMALAYA trial.October, 2022Read Article
Avelumab Plus Axitinib Shows Promising Activity in Pretreated Advanced Type B3 Thymoma and Thymic Carcinoma October, 2022Read Article